Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hunan Warrant Pharmaceutical CoSHSE:688799 +3.51%84 Return-on-Tangible-Asset is 3.64% as of Mar. 2026, which is 68% below its 10-year median of 11.47. GuruFocus rates SHSE:688799 with a GF Score™ of 84/100 and a GF Value™ of ¥32.77 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Hunan Warrant Pharmaceutical Co ranks better than 73.88% on this metric.
The historical rank and industry rank for Hunan Warrant Pharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:
SHSE:688799'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.37 Med: 11.47 Max: 17.15
Current: 8.56
During the past 12 years, Hunan Warrant Pharmaceutical Co's highest Return-on-Tangible-Asset was 17.15%. The lowest was 5.37%. And the median was 11.47%.
SHSE:688799's Return-on-Tangible-Asset is ranked better than 73.88% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.98
vs SHSE:688799: 8.56
Hunan Warrant Pharmaceutical Co (SHSE:688799) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Hunan Warrant Pharmaceutical Co Return-on-Tangible-Asset Related Terms
Hunan Warrant Pharmaceutical Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hunan Warrant Pharmaceutical Co Return-on-Tangible-Asset Chart
SHSE:688799 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Warrant Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hunan Warrant Pharmaceutical Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hunan Warrant Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Hunan Warrant Pharmaceutical Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 3.64% mean?
Hunan Warrant Pharmaceutical Co (SHSE:688799) has a Return-on-Tangible-Asset of 3.64% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Hunan Warrant Pharmaceutical Co and its competitors. This is 68% below median its historical median of 11.47. Over the past decade, Hunan Warrant Pharmaceutical Co's Return-on-Tangible-Asset has ranged from 5.37 to 17.15. According to the industry distribution chart, Hunan Warrant Pharmaceutical Co ranks #263 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 26.1%.
Is Hunan Warrant Pharmaceutical Co's Return-on-Tangible-Asset too high?
Hunan Warrant Pharmaceutical Co's current Return-on-Tangible-Asset of 3.64% is 68% below median its 10-year median of 11.47. Over the past 10 years, this metric has ranged from a low of 5.37 to a high of 17.15. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.98. Hunan Warrant Pharmaceutical Co's value of 3.64% is 22.1% above this industry median. Based on the distribution chart, Hunan Warrant Pharmaceutical Co ranks #263 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hunan Warrant Pharmaceutical Co has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hunan Warrant Pharmaceutical Co's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hunan Warrant Pharmaceutical Co ranks #263 out of 1007 companies for Return-on-Tangible-Asset. This puts Hunan Warrant Pharmaceutical Co in the upper half of its industry. The industry median Return-on-Tangible-Asset is 2.98. Hunan Warrant Pharmaceutical Co's value of 3.64% is 22.1% above this benchmark. Historically, Hunan Warrant Pharmaceutical Co's own Return-on-Tangible-Asset has ranged from 5.37 to 17.15 over the past decade. While the company's 10-year median is 11.47 vs. the industry median of 2.98, Hunan Warrant Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.98, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hunan Warrant Pharmaceutical Co's current Return-on-Tangible-Asset of 3.64% is 22.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Hunan Warrant Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hunan Warrant Pharmaceutical Co's current Return-on-Tangible-Asset is 3.64%, which is 68% below median its own 10-year median of 11.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hunan Warrant Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hunan Warrant Pharmaceutical Co (SHSE:688799) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥32.77, compared to a current price of ¥47.51 — trading 45% above its estimated fair value. The current Return-on-Tangible-Asset is 3.64%, which is 68% below median its 10-year median of 11.47 and 22.1% above the Drug Manufacturers industry median of 2.98. Hunan Warrant Pharmaceutical Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Hunan Warrant Pharmaceutical Co (SHSE:688799), the current Return-on-Tangible-Asset is 3.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hunan Warrant Pharmaceutical Co (SHSE:688799) Overvalued in 2026?
Based on GuruFocus' analysis, Hunan Warrant Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥47.51 is trading 45% above its estimated GF Value™ of ¥32.77.
GuruFocus considers Hunan Warrant Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SHSE:688799:
Return-on-Tangible-Asset: 3.64% (68% below median its 10-year median of 11.47)
GF Value™: ¥32.77 vs. price of ¥47.51 (45% above fair value)
Industry Position: 22.1% above the Drug Manufacturers median (#263 of 1007)
No single metric tells the full story. See the SHSE:688799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hunan Warrant Pharmaceutical Co Ltd is a pharmaceutical manufacturer. It is engaged in the research and development, production and sales of chemical raw materials, chemical medicine preparations and Chinese medicine preparations.
84GF Score
Get the complete analysis for SHSE:688799
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688799 has been successfully added to your 
